Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
641 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04619797 | A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer(SKYSCRAPER-06) | completed | Phase 2 / Phase 3 | 542 | Hoffmann-La RocheINDUSTRY | 21 | Jun 3, 2026 | clinicaltrials |
| NCT07076121 | A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) | active not recruiting | Phase 2 / Phase 3 |
| 470 |
| Bristol-Myers SquibbINDUSTRY |
| 36 |
| Jun 3, 2026 |
| clinicaltrials |
| NCT06474806 | Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer(uTRACE-101) | recruiting | Phase 2 | 168 | CurasightINDUSTRY | 3 | Jun 1, 2026 | clinicaltrials |
| NCT03093116 | A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements(TRIDENT-1) | recruiting | Phase 1 / Phase 2 | 500 | Turning Point Therapeutics, Inc.INDUSTRY | 19 | May 27, 2026 | clinicaltrials |
| NCT05903807 | [68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer | terminated | Phase 2 | 20 | Aalborg University HospitalOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT04824794 | GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 130 | GenmabINDUSTRY | 20 | May 19, 2026 | clinicaltrials |
| NCT06588478 | A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | recruiting | Phase 2 | 249 | Loxo Oncology, Inc.INDUSTRY | 18 | May 19, 2026 | clinicaltrials |
| NCT02308527 | Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children(BEACON) | completed | Phase 2 | 225 | University of BirminghamOTHER | 10 | May 12, 2026 | clinicaltrials |
| NCT06697301 | Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. | recruiting | Phase 2 / Phase 3 | 740 | Eikon TherapeuticsINDUSTRY | 24 | May 8, 2026 | clinicaltrials |
| NCT03580655 | (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis | completed | Phase 2 | 107 | Blueprint Medicines CorporationINDUSTRY | 12 | Apr 24, 2026 | clinicaltrials |
| NCT03778229 | Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib(SAVANNAH) | active not recruiting | Phase 2 | 367 | AstraZenecaINDUSTRY | 13 | Apr 23, 2026 | clinicaltrials |
| NCT05975073 | A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors | completed | Phase 1 / Phase 2 | 53 | AmgenINDUSTRY | 7 | Apr 22, 2026 | clinicaltrials |
| NCT03578367 | Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response. | completed | Phase 2 | 104 | Novartis PharmaceuticalsINDUSTRY | 15 | Apr 21, 2026 | clinicaltrials |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)(LIBRETTO-001) | active not recruiting | Phase 1 / Phase 2 | 857 | Eli Lilly and CompanyINDUSTRY | 16 | Apr 16, 2026 | clinicaltrials |
| NCT01244789 | Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer | active not recruiting | Phase 2 | 244 | Danish Gynecological Cancer GroupNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03401788 | A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) | active not recruiting | Phase 2 | 50 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 4 | Apr 13, 2026 | clinicaltrials |
| NCT03540420 | Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer(ACHILES) | active not recruiting | Phase 2 | 212 | Norwegian University of Science and TechnologyOTHER | 6 | Apr 13, 2026 | clinicaltrials |
| NCT04138628 | Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy(TOMBOLA) | active not recruiting | Phase 2 | 154 | Jørgen Bjerggaard JensenOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT01968109 | An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | completed | Phase 1 / Phase 2 | 1,482 | Bristol-Myers SquibbINDUSTRY | 15 | Apr 6, 2026 | clinicaltrials |
| NCT04245865 | Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer(Toco-CoR) | active not recruiting | Phase 2 | 83 | Vejle HospitalOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06116136 | A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers. | active not recruiting | Phase 1 / Phase 2 | 48 | Servier Bio-Innovation LLCINDUSTRY | 15 | Apr 3, 2026 | clinicaltrials |
| NCT03703050 | Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)(NIVO-ALCL) | active not recruiting | Phase 2 | 45 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 3 | Apr 2, 2026 | clinicaltrials |
| NCT03793478 | Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | active not recruiting | Phase 1 / Phase 2 | 65 | Daiichi SankyoINDUSTRY | 10 | Apr 1, 2026 | clinicaltrials |
| NCT04785820 | A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus | completed | Phase 2 | 190 | Hoffmann-La RocheINDUSTRY | 18 | Mar 27, 2026 | clinicaltrials |
| NCT04008797 | A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 301 | Eisai Inc.INDUSTRY | 10 | Mar 24, 2026 | clinicaltrials |
| NCT04639219 | A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations(DPT01) | active not recruiting | Phase 2 | 102 | AstraZenecaINDUSTRY | 9 | Mar 23, 2026 | clinicaltrials |
| NCT01011920 | Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma | completed | Phase 2 | 227 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 5 | Mar 19, 2026 | clinicaltrials |
| NCT03654131 | Microwave Ablation Versus Stereotactic Body Radiotherapy for Colorectal Liver Metastases in Oligometastatic Disease: a Prospective, Randomised, Phase 2 Trial(LAVA-CRLM) | active not recruiting | Phase 2 | 100 | Rigshospitalet, DenmarkOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04143711 | Study of DF1001 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 270 | Dragonfly TherapeuticsINDUSTRY | 6 | Mar 18, 2026 | clinicaltrials |
| NCT04699188 | Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation(KontRASt-01) | active not recruiting | Phase 1 / Phase 2 | 344 | Novartis PharmaceuticalsINDUSTRY | 16 | Mar 18, 2026 | clinicaltrials |
| NCT02467270 | Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses(OPTIC) | completed | Phase 2 | 283 | TakedaINDUSTRY | 21 | Mar 17, 2026 | clinicaltrials |
| NCT03590171 | International Study for Treatment of High Risk Childhood Relapsed ALL 2010 | recruiting | Phase 2 | 250 | Charite University, Berlin, GermanyOTHER | 15 | Mar 17, 2026 | clinicaltrials |
| NCT01615029 | Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 45 | Janssen Research & Development, LLCINDUSTRY | 5 | Mar 16, 2026 | clinicaltrials |
| NCT05502250 | Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission(HOVON164HL) | active not recruiting | Phase 2 | 75 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 3 | Mar 6, 2026 | clinicaltrials |
| NCT06067048 | Zanubrutinib in Primary Cold Agglutinin Disease(HOVON169CAD) | active not recruiting | Phase 2 | 25 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 4 | Mar 6, 2026 | clinicaltrials |
| NCT05218499 | Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma | completed | Phase 2 / Phase 3 | 400 | Boehringer IngelheimINDUSTRY | 22 | Mar 2, 2026 | clinicaltrials |
| NCT04742075 | Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer(DOVACC) | active not recruiting | Phase 2 | 188 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07409844 | Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer(RESET C2) | not yet recruiting | Phase 2 | 152 | Ismail GögenurOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT03930953 | A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) | active not recruiting | Phase 1 / Phase 2 | 438 | CelgeneINDUSTRY | 15 | Feb 19, 2026 | clinicaltrials |
| NCT05005442 | A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004) | completed | Phase 2 | 192 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Feb 19, 2026 | clinicaltrials |
| NCT06015542 | Self-administration of Subcutaneous Elranatamab in the Patients' Homes.(ERICA) | recruiting | Phase 2 | 20 | Thomas LundOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT03374085 | A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | terminated | Phase 1 / Phase 2 | 200 | CelgeneINDUSTRY | 11 | Feb 9, 2026 | clinicaltrials |
| NCT06697197 | A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 413 | Bristol-Myers SquibbINDUSTRY | 9 | Feb 3, 2026 | clinicaltrials |
| NCT04187404 | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma(Spencer) | terminated | Phase 1 / Phase 2 | 70 | EnteromeINDUSTRY | 8 | Jan 30, 2026 | clinicaltrials |
| NCT06771921 | A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | GenmabINDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT01897480 | A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations(Balise) | completed | Phase 2 | 168 | Eli Lilly and CompanyINDUSTRY | 9 | Jan 26, 2026 | clinicaltrials |
| NCT05276284 | Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy(TEMPLE) | completed | Phase 1 / Phase 2 | 18 | Kristoffer RohrbergOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT03056755 | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments(BYLieve) | completed | Phase 2 | 383 | Novartis PharmaceuticalsINDUSTRY | 19 | Jan 13, 2026 | clinicaltrials |
| NCT07213375 | High Dose Dexamethasone to Reduce Postoperative Pain After Video-Assisted Thoracoscopic Surgery Lobectomy /Segmentectomy(DEXTER) | recruiting | Phase 2 / Phase 3 | 80 | Rigshospitalet, DenmarkOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03899792 | A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors(LIBRETTO-121) | active not recruiting | Phase 1 / Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 11 | Jan 6, 2026 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials